IL1B and chronic kidney disease: While this study was not powered to detect changes in physical and cognitive function in response to IL-1 inhibition with rilonacept, and these measurements were only performed in a subgroup as a pilot study, the results suggest that this hypothesis should be considered further in a larger population of CKD patients.